• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

度洛西汀对广泛性焦虑障碍患者疼痛性躯体症状的短期和长期影响:三项临床试验结果

The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: results from three clinical trials.

作者信息

Beesdo Katja, Hartford James, Russell James, Spann Melissa, Ball Susan, Wittchen Hans-Ulrich

机构信息

Technische Universitaet Dresden, Institute of Clinical Psychology and Psychotherapy, Dresden, Germany.

出版信息

J Anxiety Disord. 2009 Dec;23(8):1064-71. doi: 10.1016/j.janxdis.2009.07.008. Epub 2009 Jul 14.

DOI:10.1016/j.janxdis.2009.07.008
PMID:19643572
Abstract

Generalized anxiety disorder (GAD) is associated with painful physical symptoms (PPS). These post hoc analyses of previous trial data assessed PPS and their response to duloxetine treatment in GAD patients. Studies 1 and 2 (n=840) were 9- to 10-week efficacy trials; study 3 (n=887) was a relapse prevention trial comprising a 26-week open-label treatment phase and a 26-week double-blind, placebo-controlled treatment continuation phase. Mean baseline visual analog scale scores (VAS, 0-100; n=1727) ranged from 26 to 37 for overall pain, headache, back pain, shoulder pain, interference with daily activities, and time in pain while awake. In studies 1 and 2, improvement on all VAS scores was greater in duloxetine-treated than in placebo-treated patients (p<or=0.01). In study 3, pain symptoms worsened in responders switched to placebo compared with those maintained on duloxetine (p<or=0.02). In conclusion, duloxetine was efficacious in the short- and long-term treatment of PPS, which are common in GAD patients.

摘要

广泛性焦虑障碍(GAD)与疼痛性躯体症状(PPS)相关。这些对既往试验数据的事后分析评估了GAD患者的PPS及其对度洛西汀治疗的反应。研究1和研究2(n = 840)为为期9至10周的疗效试验;研究3(n = 887)是一项预防复发试验,包括一个为期26周的开放标签治疗阶段和一个为期26周的双盲、安慰剂对照治疗延续阶段。总体疼痛、头痛、背痛、肩痛、对日常活动的干扰以及清醒时疼痛时间的平均基线视觉模拟量表评分(VAS,0 - 100;n = 1727)在26至37之间。在研究1和研究2中,度洛西汀治疗组的所有VAS评分改善均大于安慰剂治疗组(p≤0.01)。在研究3中,与继续使用度洛西汀的患者相比,换用安慰剂的缓解者疼痛症状恶化(p≤0.02)。总之,度洛西汀在PPS的短期和长期治疗中均有效,PPS在GAD患者中很常见。

相似文献

1
The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: results from three clinical trials.度洛西汀对广泛性焦虑障碍患者疼痛性躯体症状的短期和长期影响:三项临床试验结果
J Anxiety Disord. 2009 Dec;23(8):1064-71. doi: 10.1016/j.janxdis.2009.07.008. Epub 2009 Jul 14.
2
Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.度洛西汀治疗伴有具有临床意义疼痛症状的广泛性焦虑症患者的疗效。
Depress Anxiety. 2008;25(7):E1-11. doi: 10.1002/da.20337.
3
Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial.度洛西汀用于广泛性焦虑症成人患者预防复发的治疗:一项双盲安慰剂对照试验。
Eur Neuropsychopharmacol. 2008 Sep;18(9):673-81. doi: 10.1016/j.euroneuro.2008.05.002. Epub 2008 Jun 17.
4
Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.广泛性焦虑症的药物治疗:三项临床试验汇总分析中度洛西汀治疗的结果
Curr Med Res Opin. 2007 Jun;23(6):1245-52. doi: 10.1185/030079907X182202. Epub 2007 Apr 25.
5
Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.度洛西汀治疗广泛性焦虑症的疗效与安全性:一项灵活剂量、逐步滴定、安慰剂对照试验
Depress Anxiety. 2008;25(3):182-9. doi: 10.1002/da.20271.
6
Time course of depression-symptom improvement during treatment with duloxetine.度洛西汀治疗期间抑郁症状改善的时间进程。
Depress Anxiety. 2005;21(4):170-7. doi: 10.1002/da.20071.
7
Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder.一项关于度洛西汀治疗重度抑郁症患者复发预测因素的研究
J Affect Disord. 2009 Mar;113(3):263-71. doi: 10.1016/j.jad.2008.05.023. Epub 2008 Jul 14.
8
Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial.度洛西汀、文拉法辛缓释剂与安慰剂对照试验中成年广泛性焦虑症患者心理和躯体症状的改善情况研究
Psychol Med. 2009 Feb;39(2):267-76. doi: 10.1017/S0033291708003401. Epub 2008 May 19.
9
Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.每日一次服用60毫克度洛西汀治疗重度抑郁症:在中国、韩国、台湾和巴西进行的多中心、双盲、随机、帕罗西汀对照、非劣效性试验。
Psychiatry Clin Neurosci. 2007 Jun;61(3):295-307. doi: 10.1111/j.1440-1819.2007.01666.x.
10
Duloxetine in the treatment of generalized anxiety disorder.度洛西汀治疗广泛性焦虑障碍
Expert Rev Neurother. 2009 Feb;9(2):155-65. doi: 10.1586/14737175.9.2.155.

引用本文的文献

1
Evolving Concepts of Pain Management in Elderly Patients.老年患者疼痛管理理念的演变。
Curr Pain Headache Rep. 2024 Oct;28(10):999-1005. doi: 10.1007/s11916-024-01291-x. Epub 2024 Jul 5.
2
Improvements in Physical Function and Pain Interference and Changes in Mental Health Among Patients Seeking Musculoskeletal Care.寻求肌肉骨骼治疗的患者在身体功能、疼痛干扰方面的改善以及心理健康的变化。
JAMA Netw Open. 2023 Jun 1;6(6):e2320520. doi: 10.1001/jamanetworkopen.2023.20520.
3
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.
加拿大焦虑、创伤后应激障碍和强迫症管理临床实践指南。
BMC Psychiatry. 2014;14 Suppl 1(Suppl 1):S1. doi: 10.1186/1471-244X-14-S1-S1. Epub 2014 Jul 2.
4
Duloxetine in affective disorders: a naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groups.度洛西汀治疗情感障碍:一项关于精神和躯体共病、不同年龄组联合用药及耐受性的自然主义研究。
Clin Pract Epidemiol Ment Health. 2012;8:120-5. doi: 10.2174/1745017901208010120. Epub 2012 Nov 2.
5
Predictors of Treatment with Duloxetine or Venlafaxine XR among Adult Patients Treated for Depression in Primary Care Practices in the United Kingdom.英国初级医疗实践中接受抑郁症治疗的成年患者使用度洛西汀或文拉法辛缓释剂治疗的预测因素
Depress Res Treat. 2012;2012:815363. doi: 10.1155/2012/815363. Epub 2012 Jun 7.